Biography and Research Information
OverviewAI-generated summary
Alicia L. Graham's research focuses on cancer immunotherapy, particularly in the context of hepatocellular carcinoma. She investigates the potential of repurposing live attenuated trivalent MMR vaccine as a cost-effective cancer immunotherapy. Graham also studies the enhancement of immune response and survival in hepatocellular carcinoma through the use of novel oncolytic Jurona virus in conjunction with immune checkpoint blockade. Her work includes a comprehensive proteogenomic analysis to assess the in vivo safety and immunoactivity of oncolytic Jurona virus in hepatocellular carcinoma.
Graham has a h-index of 3 with 4 total publications and 44 total citations. She has collaborated with researchers including Steven R. Post, Martin J. Cannon, Mulu Z. Tesfay, and Camila Simões, all from the University of Arkansas for Medical Sciences, with whom she shares 3 co-authored publications.
Metrics
- h-index: 3
- Publications: 4
- Citations: 45
Selected Publications
-
Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade (2024)
-
Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy (2022)
Collaboration Network
Top Collaborators
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
Similar Researchers
Based on overlapping research topics